Blood and Marrow Transplant Group of Georgia
9
1
1
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
11.1%
1 terminated/withdrawn out of 9 trials
87.5%
+1.0% vs industry average
0%
0 trials in Phase 3/4
114%
8 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (9)
CAR T-cell Therapy in Patients With Renal Dysfunction
Role: collaborator
Reduced Intensity Conditioning Transplant Using Haploidentical Donors
Role: collaborator
FOB in HSCT and Leukemia Patients With Acute Respiratory Symptoms and Pulmonary Infiltrates
Role: collaborator
Palonosetron, Ondansetron, and Dexamethasone for Delayed Nausea and Vomiting in Autologous Transplant Patients
Role: collaborator
Rituximab for the Primary Treatment of Denovo Extensive Chronic Graft Versus Host Disease (GVHD)
Role: collaborator
Total Body Irradiation/Fludarabine Based Ablative Haploidentical Transplant for Hematologic Diseases
Role: collaborator
Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant
Role: collaborator
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer
Role: collaborator
Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer
Role: collaborator
All 9 trials loaded